Le Lézard51m
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the ...
MassDevice23m
Abbott is making an IVL play with FDA IDE nod
Abbott (NYSE: ABT) received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy ...